Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02452671 · ClinicalTrials.gov registry record

Observational Plan to Obtain Clinical Experience and Follow up Data on the Use of the ProxiFuse Hammer Toe Device

A clinical trial, sponsored by Cartiva.

Terminated
Registry status
15
Enrollment target

NCT02452671: Clinical Trial study, sponsored by Cartiva.

NCT02452671 is a clinical trial that was terminated before completion, run by Cartiva. The registered enrollment target is 15 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02452671 was terminated before completion, sponsored by Cartiva.

TERMINATED
Registry status
15 participants
Enrollment target

Study Summary

This is a multi-center, non-randomized, observational study to further evaluate the effectiveness and safety of the Proxifuse Hammer Toe Device when utilized for bone fixation. Approximately 4 US sites will participate. The primary endpoint will evaluate the 6 month post surgery change from baseline in the PROMIS Pain Interference computerized adaptive test (CAT) score.

Trial Details

FieldValue
Enrollment Target 15 participants
Start Date 2015-06
Est. Completion 2017-02
Cartiva

3 total trials

Why NCT02452671 stopped before completion

NCT02452671 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 15 participants, a relatively small participant target.

The record links to 0 conditions, and to 0 interventions.

NCT02452671 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02452671 about?

NCT02452671 is a clinical study titled "Observational Plan to Obtain Clinical Experience and Follow up Data on the Use of the ProxiFuse Hammer Toe Device". This is a multi-center, non-randomized, observational study to further evaluate the effectiveness and safety of the Proxifuse Hammer Toe Device when utilized for bone fixation. Approximately 4 US sites will participate. The primary endpoint will evaluate the 6 month post surgery change from baseline...

What is the current status of trial NCT02452671?

This trial is currently terminated. The enrollment target is 15 participants. The study started on 2015-06. Estimated completion is 2017-02.

Who is sponsoring clinical trial NCT02452671?

This trial is sponsored by Cartiva, which has 3 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01889381 · 15 participants · Phase 2

    Human Craniomaxillofacial Allotransplantation

  • NCT02530073 · 15 participants · NA

    Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH

  • NCT02535936 · 15 participants · NA

    Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy

  • NCT02918474 · 15 participants · NA

    Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02452671, the US trial registry maintained by the National Library of Medicine. NCT02452671 (small enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.